Angiotensin-receptor blockers: Benefits beyond lowering blood pressure

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 9, 2005, Pages 825-832

  Silverstein, Russell L ^a   Ram, C Venkata S ^a,b  

^a Dallas Nephrology Associates   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN POTASSIUM; NATEGLINIDE; OLMESARTAN; PLACEBO; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ACUTE HEART INFARCTION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MICROALBUMINURIA; PROGNOSIS; REVIEW; RISK REDUCTION; STROKE;

EID: 25844476008     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.9.825     Document Type: Review

References (33)

1. McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998; 56:847-869.
2. McClellan KJ, Balfour JA. Eprosartan. Drugs 1998; 55:713-718.
3. Markham A, Spencer CM, Jarvis B. Irbesartan: an updated review of its use in cardiovascular disorders. Drugs 2000; 59:1187-1206.
4. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51:820-845.
5. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62:1345-1353.
6. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61:1501-1529.
7. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54:299-311.
8. Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998; 32:1060-1066.
9. Hansson L, Smith DH, Reeves R, et al. Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy. Arch Intern Med 2000; 160:1654-1658.
10. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89(suppl 2A):3A-10A.
11. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003; 12:70-88.
12. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
13. Bella IN, Palmieri V, Wachtell K, et al. Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study. J Hum Hypertens 2004; 18:411-416.
14. Julies S, Alderman MH, Beavers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol 2004; 43:1047-1055.
15. Malmqvist K, Kahan T, Edner M, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19:1167-1176.
16. Lithell H, Hansson L, Skoog I, et al: SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): outcomes in patients not receiving add-on therapy after randomization. J Hypertens 2004; 22:1605-1612.
17. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2010-2011.
18. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363:2022-2031.
19. Prisant LM. Preventing type II diabetes mellitus. J Clin Pharmacol 2004; 44:406-413.
20. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
21. American Diabetes Association. Position statement. Hypertension management in adults with diabetes. Diabetes Care 2004; 27(suppl 1):S65-S67.
22. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
23. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
24. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
25. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678.
26. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124.
27. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360:752-760.
28. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
29. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-752.
30. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587.
31. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
32. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759-766.
33. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-771.